Giuseppe Lamberti
Giuseppe Lamberti is an expert in Oncology at Policlinico S.Orsola-Malpighi (Italy). As of October 2026, ScienceLeadR ranks Giuseppe Lamberti in the top 1% of experts worldwide for Lung Neoplasms and Thoracic Neoplasms. Giuseppe Lamberti has authored 292 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 1 of them ongoing. SLR score: 942 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Endocrinology - Immunology - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2026
Number : 292
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Streptozotocin-based chemotherapy in advanced PanNETs: a systematic review and meta-analysis. PMID 42895108 — drug therapy, streptozocin, outcome assessment, health care, therapeutics, chemotherapy | Endocr Relat Cancer | 2026 | 0 |
| How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes? PMID 42770502 — cells, lung, neoplasms, lung neoplasms, small cell lung carcinoma, therapeutics, etoposide | Expert Rev Anticancer Ther | 2026 | 0 |
| Niacin deficiency in carcinoid syndrome: Definitions, biomarkers, and a pragmatic framework for clinical assessment. PMID 42735610 — pellagra, vitamins, niacin, biomarkers, carcinoid tumor | Nutrition | 2026 | 0 |
| Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm. PMID 42607265 — gastroenterology, progression-free survival, neoplasms, neuroendocrine tumors, wounds and injuries, endoscopic mucosal resection | Clin Transl Gastroenterol | 2026 | 0 |
| Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors. PMID 42592685 — registries, lung, temozolomide, pharmaceutical preparations, neoplasms, drug therapy, neuroendocrine tumors, therapeutics, chemotherapy | Thorac Cancer | 2026 | 0 |
Clinical Studies 4
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive stage Small Cell Lung Cancer (ES SCLC) NCT06663098 — cells, lung, area under curve, neoplasms, drug therapy, maintenance, lung neoplasms, small cell lung carcinoma, antibodies, monoclonal, therapeutics, etoposide, carboplatin, chemotherapy, carcinoma | Phase 2 | Recruiting | 2025 |
LeadR Networks
Main global connection map